Jianhui Li

Institute of Life Sciences, Jiyang Colloge of Zhejiang A&F University, Zhuji, 311800, Zhejiang, China
Author    Correspondence author
GMO Biosafety Research, 2024, Vol. 15, No. 2   
Received: 21 Feb., 2024    Accepted: 07 Apr., 2024    Published: 19 Apr., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Genetically modified organisms (GMOs) have become pivotal in biomedical research, offering significant advancements in understanding disease mechanisms and developing novel therapies. This study explores the development and application of genetically modified (GMO) animals, focusing on their role in disease modeling, drug discovery, and regenerative medicine. Key techniques, including CRISPR-Cas9 and gene knockout, are discussed, alongside ethical considerations in GMO animal creation. A case study on Alzheimer’s disease highlights the contributions of GMO mice to therapeutic progress. The study also addresses biosafety concerns, such as genetic drift and environmental risks, emphasizing the need for robust containment strategies and regulatory frameworks. Methodologies for biosafety assessment are examined, including in vivo and in vitro testing, with a focus on improving risk management protocols. Challenges in predicting long-term effects and gaps in current assessment strategies are identified, with suggestions for overcoming these through emerging technologies. The study concludes by recommending interdisciplinary collaboration to enhance the safe and ethical application of GMO animals in biomedical research.

GMO animals; Biomedical research; Biosafety assessment; CRISPR-Cas9; Disease models